Cyclerion Therapeutics, Inc. (CYCN) Form 10-Q — May 12, 2026
Cyclerion Therapeutics reported a net loss of $3.2 million for the quarter ended March 31, 2026, with zero revenue compared to $81,000 in the prior-year period. The company holds $2.8 million in cash and cash equivalents, which management estimates will fund operations only into the third quarter of 2026. The company entered into a definitive merger agreement with Korsana Biosciences, Inc. on April 1, 2026, which will result in Cyclerion changing its name to Korsana Biosciences, Inc.
Key figures
- Revenue
- 0
- Cash Position
- 2823000
- Akebia Milestone Received
- $1,000,000
- Korsana Pre Closing Financing
- $380,000,000
- Cyclerion Ownership Post Merger
- 1.5%
Price after filing
Close on the filing date to close N calendar days later (from $3.18). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.